Last updated: 11/07/2018 09:33:29
Gabapentin and donepezil combination on experimental human pain models
Clinicaltrials.gov ID
EudraCT ID
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A randomized, double blind, placebo controlled study to investigate the effect of donepezil and gabapentin combination on an experimental pain model in healthy subjects
Trial description: This study will compare the effects of gabapentin alone, and gabapentin + donepezil given together in two types ofexperimental electrical pain tests in up to 48 healthy male subjects (after 24 recruited in the first cohort an interim analysis will be performed).The study is a randomized, double blind, placebo controlled, 3 was cross-over design study with incomplete block design and 4 treatment options. Placebo, gabapentin alone (lower dose and higher dose) or gabapentin (lower dose) with donepezil.
Primary purpose:
Basic Science
Trial design:
Crossover Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:
Area of pin-prick hyperalgesia
Timeframe: Change from baseline visit to day 14 of treatment sessions
Area of touch-evoked allodynia
Timeframe: Change from baseline visit to day 14 of treatment sessions
Secondary outcomes:
Pain threshold
Timeframe: Change from baseline visit to day 14 of treatment sessions
Ongoing pain intensity rating
Timeframe: Change from baseline visit to day 14 of treatment sessions
Pain Tolerance
Timeframe: Change from baseline visit to day 14 of treatment sessions
Pain Temporal Summation
Timeframe: Change from baseline visit to day 14 of treatment sessions
Intensity of flare
Timeframe: Change from baseline visit to day 14 of treatment sessions
Interventions:
Enrollment:
48
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Yvonne Boyle, Disala Fernando, Hazel Kurz, Sam Miller, Mauro Zucchetto, Jim Storey.The effect of a combination of gabapentin and donepezil in an experimental pain model in healthy volunteers: results of a randomized controlled trial.Pain.2014;155(12):2510-2516
Medical condition
Pain, Neuropathic
Product
donepezil, donepezil/gabapentin, gabapentin
Collaborators
Not applicable
Study date(s)
October 2011 to July 2012
Type
Interventional
Phase
1
Participation criteria
Sex
Male
Age
18 - 55 years
Accepts healthy volunteers
Yes
- 1. Male between 18 and 55 years of age inclusive, at the time of signing the informed consent.
- 2. Body weight ≥ 50 Kilogram (kg) and BMI within the range 18.5-29.9 Killogram per square meter (kg/m2) (inclusive).
- 1. The subject has either a previous disease or current medical condition, which as judged by the Investigator, may compromise safety or affect the interpretation of efficacy data.
- 2. History of known or suspected seizures, including infantile febrile, unexplained significant and recent loss of consciousness or history of significant head trauma with loss of consciousness or a family history (first degree relative) of epilepsy or seizures (fits).
Inclusion and exclusion criteria
Inclusion criteria:
- 1. Male between 18 and 55 years of age inclusive, at the time of signing the informed consent. 2. Body weight ≥ 50 Kilogram (kg) and BMI within the range 18.5-29.9 Killogram per square meter (kg/m2) (inclusive). 3. Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, psychiatric history, psychiatric evaluation, laboratory tests and cardiac monitoring. 4. Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin ≤ 1.5x Upper Limit of Normal (ULN) 5. QT duration corrected for heart rate by Bazett's formula (QTcB) or QT duration corrected for heart rate by Fridericia's formula (QTcF) < 450 milli second (msec).
Exclusion criteria:
- 1. The subject has either a previous disease or current medical condition, which as judged by the Investigator, may compromise safety or affect the interpretation of efficacy data. 2. History of known or suspected seizures, including infantile febrile, unexplained significant and recent loss of consciousness or history of significant head trauma with loss of consciousness or a family history (first degree relative) of epilepsy or seizures (fits). 3. Abnormalities in 12-lead Electrocardiogram (ECG) 4. Systolic blood pressure (BP) below 90 or above 160mm Hg, or diastolic blood pressure below 50 or above 100 millimeters of mercury (mmHg). 5. History of sensitivity to any of the study medications 6. History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of >21 units. One unit is equivalent to 8 g of alcohol: a half-pint (~240 millil litre [ml]) of beer, 1 glass (125 ml) of wine or 1 (25 ml) measure of spirits. 7. A positive pre-study drug/alcohol screen at the screening visit. 8. Excessive caffeine drinkers (~5 or more cups a day) . 9. Excessive smokers (>5 /day) 10. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John’s Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to screening, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety. 11. Use of any topical steroid or capsaicin preparations in the previous 30 days to screening, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety. 12. The subject is needle phobic 13. The subject is unable to tolerate the electrical hyperalgesia model or nerve stimulation, including anxiety or atypical response to the stimulation on the training at the screening visit. 14. The subject does not produce an area of allodynia or hyperalgesia to the electrical hyperalgesia model during the screening session. 15. Subject who, in the investigator/designee's judgement, poses a significant suicide risk. Evidence of serious suicide risk may include any history of suicidal behaviour and/or any evidence of suicidal ideation on any questionnaires e.g. type 4 or 5 on the C-SSRS in the last 6 months. 16. The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the baseline session in the current study: 90 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer). 17. Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 84 day period. 18. A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening 19. Unwillingness or inability to follow the procedures outlined in the protocol.
Trial location(s)
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2012-03-07
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Results for study 115484 can be found on the GSK Clinical Study Register.
Click hereAccess to clinical trial data by researchers
Visit website